diarrhea and tirzepatide on (Mounjaro) affects approximately 23–31% of patients is typically mild to moderate, transient, and most common during dose escalation. , It rarely requires discontinuation How to Manage Diarrhea on

Also, in a real-world cohort of GLP-1 therapy users, the average total body weight loss was ~12.2%, and about 17.8% of patients were classified as non-responders

My team and I set out to test whether GLP-1 drugs medications like semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound), originally developed for diabetes and then approved for obesity could do what no existing addiction treatment does: curb craving itself

Try adding a scoop of beans to salads or making a lentil soup for lunch

This design gives you the incredible ability to throw a ball, reach overhead, or swing a club, but it comes at a steep price: inherent instability